<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
INCLUDES NEW CELL TYPES FOR STUDYING MOLECULAR DISEASE SIGNATURES FOR DISCOVERY OF DISEASE-MODIFYING THERAPIES FOR NEURODEGENERATIVE DISEASES TRIGGERS US$ 9.0 M PAYMENT TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / October 8, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its collaboration with Bristol Myers Squibb (NYSE: BMY) has been expanded to include a new cell type, triggering a payment of $ 9.0 m to Evotec. The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases.
...read full article on Accesswire
